Smith & Nephew
SNN
Market cap $13.5B

30.92 USD

-0.68

2.15%

Updated Jul 30, 3:20 PM EDT

1 day

-2.15%

5 days

-2.24%

1 month

0.95%

3 months

10.35%

6 months

20.50%

Year to date

26.72%

1 year

7.51%

5 years

-24.44%

10 years

-15.12%

About: Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Employees: 17,349

Healthcare Medical Devices

0

Funds holding %

of 7,323 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

70% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 23

15% more repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 73

8% more capital invested

Capital invested by funds: $827M [Q4 2024] → $891M (+$63.4M) [Q1 2025]

4% more funds holding

Funds holding: 213 [Q4 2024] → 222 (+9) [Q1 2025]

0.26% less ownership

Funds ownership: 3.85% [Q4 2024] → 3.59% (-0.26%) [Q1 2025]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]

89% less call options, than puts

Call options by funds: $14K | Put options by funds: $133K

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$28

9%

downside

Avg. target

$28

9%

downside

High target

$28

9%

downside

1 analyst rating

0 positive

0%

1 neutral

100%

0 negative

0%

Canaccord Genuity

Caitlin Cronin

9%downside

$28

Hold

Maintained

1 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about SNN published over the past 30 days

Zacks Investment Research

SNN or SYK: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Products stocks are likely familiar with Smith & Nephew (SNN) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?

SNN or SYK: Which Is the Better Value Stock Right Now?

Zacks Investment Research

Should Value Investors Buy Smith & Nephew SNATS (SNN) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Smith & Nephew SNATS (SNN) Stock?

Proactive Investors

Smith & Nephew: Quiet start for med-tech giant as pressure mounts

It was a quiet start to the week for shares in Smith & Nephew PLC (LSE:SN). But perhaps it is the calm before the storm for the medical devices giant, which faces a shareholder revolt.

Smith & Nephew: Quiet start for med-tech giant as pressure mounts

Zacks Investment Research

SNN or ESLOY: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Products sector have probably already heard of Smith & Nephew (SNN) and EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two stocks is more attractive to value investors?

SNN or ESLOY: Which Is the Better Value Stock Right Now?

Zacks Investment Research

Are Investors Undervaluing Smith & Nephew SNATS (SNN) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Are Investors Undervaluing Smith & Nephew SNATS (SNN) Right Now?

Smith+Nephew expands market-leading fixation strength of Q-FIX™ All-Suture Anchor portfolio with new knotless option

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the release of its Q-FIX KNOTLESS All-Suture Anchor for soft tissue-to-bone fixation indications across multiple joint spaces including Shoulder, Hip, and Foot & Ankle.

Smith+Nephew expands market-leading fixation strength of Q-FIX™ All-Suture Anchor portfolio with new knotless option

Zacks Investment Research

SNN Expands Orthopedic Portfolio With Advanced Tibia Nailing System

Smith + Nephew launches TRIGEN MAX, the only tibia nailing system with side-specific nails for precise, low-impact fracture repair.

SNN Expands Orthopedic Portfolio With Advanced Tibia Nailing System

Zacks Investment Research

SNN vs. GEHC: Which Stock Is the Better Value Option?

Investors interested in Medical - Products stocks are likely familiar with Smith & Nephew (SNN) and GE HealthCare Technologies (GEHC). But which of these two stocks is more attractive to value investors?

SNN vs. GEHC: Which Stock Is the Better Value Option?

Zacks Investment Research

Is Smith & Nephew SNATS (SNN) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Smith & Nephew SNATS (SNN) Stock Undervalued Right Now?

Smith+Nephew's new TRIGEN™ MAX Tibia Nailing System brings ‘next-level nailing' to trauma surgeons repairing tibial fractures

The future of fracture fixation with novel side-specific nails featuring variable angle locking technology Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of its new TRIGEN MAX Tibia Nailing System for stable and unstable fractures of the tibia, including the shaft. It is the only system to now offer trauma surgeons the choice of side-specific (right and left) nails for anatomic screw trajectories, which help to optimize fragment fixation and minimize soft tissue irritation with headless and low-profile screw options.1, 2 The TRIGEN MAX Tibia Nailing System aims to streamline operative procedures and provide efficiency through surgeon-centered design of components and instrumentation, including: Two-piece modular drop system to help when using ancillary instruments and aid visualization.

$Smith+Nephew's new TRIGEN™ MAX Tibia Nailing System brings ‘next-level nailing' to trauma surgeons repairing tibial fractures$

See News Rankings

Charts implemented using Lightweight Charts™